1 not yet recruiting. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Not yet recruiting 1 |
Follow Circulating Tumor Cell: new trials by email Literature Review of Circulating Tumor Cell trials Research Report on Circulating Tumor Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC Osimertinib 80 MG, Bevacizumab - Non Small Cell Lung Cancer, Circulating Tumor Cell | Early Phase 1 | Not yet recruiting | Second Affiliated Hospital of Nanchang University | 100 | 2024-08-20 | 2024-08-16 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplastic Cells, Circulating (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Bevacizumab (1) · osimertinib (1)
Second Affiliated Hospital of Nanchang University (1)